tirzepatide news 2025 New clinical trial: Zepbound (tirzepatide) helped adults lose an average of 20.2% of their body weight—around 50 lbs—over 72 weeks, outperforming Wegovy's 13.7% (~33 lbs). Credit to: https://www.healthline.com/health-news/zepbound-wegovy-weight-loss 📣 BIG NEWS IN OBESITY

[1] [3] It is essential to understand that retatrutide has not received marketing authorisation from the Medicines and Healthcare products Regulatory Agency (MHRA) , which is the body responsible for licensing medicines for use in the UK following the UK's departure from the European Union

Without antioxidants to neutralize them, free radicals accumulate and cause oxidative damage that contributes to aging and disease

Broader metabolic coverage Metabolic syndrome involves multiple interconnected dysfunctions: insulin resistance, dyslipidemia, hypertension, visceral obesity, and chronic inflammation

Talk with your healthcare provider or registered dietitian to personalize your plan and achieve your goals.